Genprex

Biotech Showcase™ 2019 Lipid Nanoparticle-Encased TUSC2 Gene Underpins Phase II NSCLC asset

Speaking on the sidelines of Biotech Showcase 2019, Julien Pham, President and COO of Genprex, describes how the company is using a technology platform which wraps the TUSC2 gene in a cholesterol nanoparticle to create Oncoprex™ which, in combination with erlotinib, is in Phase II testing against NSCLC.